Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Incannex Healthcare Inc.

35 indications, side-by-side phase, drug & LoA

$3.83

+0.02 (+0.52%)

D 30Pipeline Score Overvalued Biotech · Clinical
Market Cap
42.12 M
EPS
-17.18
P/E Ratio
-
Value Trade
535.43 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    321.00 K

  • Total Assets

    80.28 M

  • Total Liabilities

    5.05 M

  • Equity

    75.23 M

  • D/E Ratio

    12,345

-8.57 %
Week
-6.88 %
1 Month
-59.3 %
3 Month
-64.44 %
6 Month
-99.82 %
5 Year
-99.82 %
All Time
Cash Data
Healthy

  • Cash Position

    74.45 M

  • Monthly Burn

    1.35 M

  • Runway

    54.3 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
359.79 K
52 Week Range
2.49 - 49.80
% held by Insiders
0.94 %
% held by Institutions
0.37 %
Enterprise Value
-32.22 M
Total Shares
358.37 M
Short %
0.24 %
Float Shares
354.42 M
Company Description
HQ: 8 CENTURY CIRCUIT, NORWEST NSW
Employees:12
https://www.incannex.com.au

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D30
Pipeline Score
$9M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 33%
Micro Cap
(rank 607 of 905)
Percentile Rank
Incannex Healthcare Inc. faces pipeline headwinds (30/100), with $37M risk-adjusted pipeline value, led by IHL-42X Low Dose in Obstructive Sleep Apnea (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IHL-42X Low Dose
Small molecule		Obstructive Sleep ApneaPhase 2NCT0614610127% $37M ACTIVE NOT_RECRUITING 685 VERY_FAST B (76) Dec 1, 2026MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IXHL
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IXHL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IXHL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IXHL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IXHL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IXHL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Incannex Healthcare Inc. (IXHL) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IXHL ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Sleep Disorders #10 of 14 PHASE 2 IHL-42X Low Dose + Dronabinol + Acetazolamide
LLY NVO AMGN
$3.95B 0.91 FOLLOWER